Contact
 
News about the Enterprise

Webinar Announcement: The anti-HIV Activity of Natural Killer Cells - September 22, 2014

The Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) invite you to join their webinar on “The anti-HIV activity of Natural Killer cells: Their role in protection from and control of HIV infectionwith Dr.

The Immune Space: A Concept and Template for Rationalizing Vaccine Development - August 21, 2014

The Enterprise and partners published a paper on "The Immune Space: A Concept and Template for Rationalizing Vaccine Development".  The “immune space template” proposed provides a standardized approach by which the quality, level, and durability of immune responses elicited in early human trials by a candidate vaccine can be described.

Keystone Symposium on HIV Vaccines: Adaptive Immunity and Beyond - April 22, 2014

The Keystone Symposium on HIV Vaccines: Adaptive Immunity and Beyond was held in Banff, Canada on 9-14 March, 2014.  The meeting’s main focus was the coordinated action of the humoral, cellular, and innate arms of the immune system in response to HIV vaccines or infection.  We bring you several stories that made a splash at the meeting and were discussed both in the conference center hallways and on the skiing lifts.

The game of tag and read

HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission - April 14, 2014

In January 2013, the Enterprise held a consultation in Uganda on conducting efficacy trials of HIV prevention approaches in infants born to HIV-positive mothers in resource-limited settings (see the full report at http://www.vaccineenterprise.org/content/prevention-trials-infants).

CIHR-Bill & Melinda Gates Foundation launch team grant funding opportunity on Mucosal Immunology for HIV Vaccine Development - April 9, 2014

In the field of HIV vaccines, the prevention of HIV through mucosal infection has emerged as a critical area for investigation.  Mucosal surfaces, such as vaginal and rectal surfaces, are primary sites of HIV infection and offer potentially critical opportunities for protection.  A better understanding of early events in HIV exposure may be leveraged to develop new strategies to block infection or establish early, stringent control of HIV and prevent further spread.

Scientific Highlights of AIDS Vaccine 2013, Barcelona - February 21, 2014

AIDS Vaccine 2013 was hosted by the Global HIV Vaccine Enterprise together with the Catalan Program for HIV Vaccine Research (HIVACAT) at the Barcelona International Convention Center from 7 – 10 October.  More than 900 researchers, funders, advocates and policymakers met in Barcelona for the 13th AIDS Vaccine conference at a time of significant progress and challenges in HIV prevention research.  

Symposium on Nonhuman Primate Models for AIDS, November 2013 - February 21, 2014

Highlights from the 31st Annual Symposium on Nonhuman Primate Models for AIDS held on 3–6 November 2013, in Atlanta, Georgia (www.yerkes.emory.edu/aidsconf/). The symposium was divided into six sessions with 54 oral presentations and 83 poster presentations. Louis Picker was the keynote speaker and Beatrice Hahn made a special presentation. Here we report on five presentations organized around two themes.

Enterprise Calls for Timely Topics Proposals -- Help Identify Topics Critical to Advancing HIV Vaccine R&D - February 12, 2014

349
Timely Topics in HIV Vaccines is a science strategy program of the Global HIV Vaccine Enterprise, convening experts to respond to emerging priority issues in the field. Through an open call for proposals, the Enterprise aims to identify the most important strategic topics that need to be discussed and explored in a collaborative fashion.

Enterprise Webinar on Antibody Durability - December 3, 2013

The Enterprise held a webinar to share highlights from the recent thinktank on antibody durability, http://www.vaccineenterprise.org/timely-topics/antibody-durability/index.htm.

 

Enterprise Webinar on Strategic Directions for Therapeutic Vaccines Research - November 14, 2013

The Enterprise together with AVAC, the Bill & Melinda Gates Foundation and the Treatment Action Group (TAG) hosted a consultation in September on strategic directions for therapeutic vaccines research.  Join us on Monday, 18 November at 12:00 EST for a webinar to share highlights from the consultation. You can register for the webinar here, https://cc.readytalk.com/cc/s/registrations/new?cid=68wm0ch6bj72.

Syndicate content
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account